Immediate response requested: Your ballot for KMS election of officers
The KMS Nominating Committee presents the following slate of candidates for KMS annual elections to be held on Monday, January 24, 2022, beginning at 5:30 p.m. at the KMS Annual Meeting to be held in the Vanguard Ballroom at the Cyrus Hotel, 920 S Kansas Avenue in Topeka. Trustees and officers will serve two-year terms. (*As indicated below, currently serves on the Board, and is eligible for re-election.)
President Mark Brady, MD; Anesthesiology-Overland Park
President-elect G. Aron Fast, MD; Family Medicine-Hesston
Central District Trustee I Chad Schroeder, MD; Family Medicine-Salina*
Eastern District Trustee I Scott Coates, MD; General Surgery-Parsons*
Western District Trustee I Jill Linville, MD; Family Medicine-Lakin*
AMA Delegate Art Snow, MD; Family Medicine-Shawnee Mission*
AMA Delegate Richard Warner, MD; Psychiatry-Overland Park*
Join your physician leader peers at Advocacy Day
KMS Advocacy Day is set for January 25 in Topeka. Among other things, Advocacy Day is your chance to meet with legislative leaders, to meet with your specialty society peers, and to hear from KMS leadership about the upcoming legislative session. While some specialty societies may also hold events later in the year, Advocacy Day is the one event of the year for all Kansas physicians. The event schedule and registration is available here: www.kmsonline.org/AdvocacyDay. We hope you will join us!
Kansas allocated Paxlovid and Molnupiravir oral treatments for COVID-19
Officials from the Kansas Department of Health and Environment (KDHE) have advised KMS that the federal government recently allocated the state both Paxlovid and Molnupiravir and initial distribution will be through the federal pharmacy partnership.
These two oral therapeutics were authorized in late December and may be effective for treatment of high-risk patients with mild to moderate COVID-19 infections who are at high risk of progression to severe COVID-19.
Yesterday, KDHE officials announced the first availability of Paxlovid in Kansas. KDHE officials advised KMS that, as further shipments are received by pharmacies, it is expected that more location-based availability will be announced. In the meantime, the latest information on Paxlovid is available here and on Molnupiravir here.
The U.S. Food and Drug Administration (FDA) issued emergency use authorizations for these treatments on Dec. 23, under which physicians must meet certain prescribing criteria. Due to limited quantity, the National Institutions of Health (NIH) also created guidelines for patient prioritization.
The Paxlovid treatment is authorized for children ages 12 and older (weighing at least 88 pounds) as well as adults. It must start within five days of symptom onset and consists of three pills taken twice daily for five days. More information can be found in the FDA’s fact sheet and FAQ document.
The Molnupiravir treatment is authorized for adults (18 and older). It must start within five days of symptom onset. Physicians should take special precautions when prescribing to women and men of child-bearing age as the medication was found to cause fetal harm in animal studies. More information can be found in the FDA’s fact sheet and FAQ document.
Updated 2022 Specialty Impact Analysis and Medicare Conversion Factor
The American Medical Association (AMA) recently released this specialty impact analysis of the Protecting Medicare and American Farmers from Sequester Cuts Act for January 1, 2022. The measure avoided a 4% statutory cut from the PAYGO provisions, extended the moratorium on the 2% Medicare payment sequester, and mitigated the 3.75% Medicare physician payment cut. Note: the analysis is focused on the impact at the beginning of the year.Also, CMS has now released the new 2022 Physician Fee Schedule (PFS) conversion factor of $34.6062 and Anesthesia conversion. factor of $21.5623.
New CPT Modifier 93 - Audio-Only Service
A new modifier was recently accepted by the Current Procedural Terminology (CPT) Editorial Panel to describe real-time telemedicine services between a patient and a physician or other qualified health care professional rendered via audio-only. This new modifier is effective January 1, 2022. The full description of the new “CPT Modifier 93” is available here on the AMA website.
• • •